slCeMM1 is a selective SLC16A3 ( MCT4 ) inhibitor. slCeMM1 inhibits lactate transport, induces intracellular lactate accumulation, reduces viability of SLC16A3-dependent cells, and inhibits growth of SLC16A3-dependent cells. slCeMM1 can be used for the research of rheumatoid arthritis and cancer [1].
In Vitro, slCeMM1 (serial dilutions; 72 h) potently and selectively inhibits viability of SLC16A3-dependent HAP1 SLC16A1-/- cells with an IC50 of 0.88 μM, while having no effect on HAP1 cells dependent on SLC16A1, SLC16A7, or SLC16A8[1]. slCeMM1 (serial dilutions; 6 h) induces intracellular lactate accumulation in SLC16A3-dependent HAP1 SLC16A1-/- cells with an IC50 of 91 nM, confirming inhibition of SLC16A3-mediated lactate export[1].
References:
[1]. Dvorak V, et al. Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors. Cell Chem Biol. 2023;30(8):953-964.e9.
In Vitro, slCeMM1 (serial dilutions; 72 h) potently and selectively inhibits viability of SLC16A3-dependent HAP1 SLC16A1-/- cells with an IC50 of 0.88 μM, while having no effect on HAP1 cells dependent on SLC16A1, SLC16A7, or SLC16A8[1]. slCeMM1 (serial dilutions; 6 h) induces intracellular lactate accumulation in SLC16A3-dependent HAP1 SLC16A1-/- cells with an IC50 of 91 nM, confirming inhibition of SLC16A3-mediated lactate export[1].
References:
[1]. Dvorak V, et al. Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors. Cell Chem Biol. 2023;30(8):953-964.e9.